CPC Scientific

CPC Scientific is a contract research, development, and manufacturing organization focused on peptides and oligonucleotides. The company supports customers across research, clinical-development, and commercial-manufacturing programs through custom synthesis, process development, and manufacturing services. Its work is directed toward pharmaceutical, biotechnology, academic, and related life-sciences applications, including research materials, investigational products, active pharmaceutical ingredients, and other specialized peptide materials. The CPC Scientific Group was founded in 2001, while the United States company was established in 2005 by Shawn Lee, Ph.D. Its early activities included supplying research-grade custom peptides, catalog peptides, and Fmoc-protected amino acids. These offerings positioned the business as a specialist supplier for researchers who require chemically defined peptide building blocks or custom sequences rather than standardized small-molecule products. A significant development came in 2006, when CPC Scientific opened a Good Manufacturing Practice facility in Hangzhou, China. The facility expanded the company’s ability to support peptide production for clinical use and provided a manufacturing base for pharmaceutical-grade materials. The Hangzhou site underwent its first inspection by the United States Food and Drug Administration in 2011. Following that inspection, CPC Scientific began supplying pharmaceutical-grade peptides to customers in the United States. The site subsequently passed a fourth FDA inspection on March 17, 2016. CPC Scientific’s manufacturing platform is principally based on solid-phase peptide synthesis, or SPPS. The method, first described by Robert Bruce Merrifield in 1963, assembles peptide chains step by step on a solid support. SPPS is particularly useful for producing complex or relatively long sequences and can be applied to research compounds, active pharmaceutical ingredients, investigational drugs, and other high-value peptide materials. Company-associated researchers have also published work involving peptide-synthesis methods, including research related to hydrocarbon-stapled peptides. Materials manufactured by CPC Scientific have been used and cited in scientific studies. The company continued its quality and regulatory development in the 2020s. In 2024, it completed a fifth United States FDA inspection and was also inspected by Australia’s Therapeutic Goods Administration. In 2025, CPC Scientific obtained ISO 22716:2007 Cosmetic Good Manufacturing Practice certification for the manufacture of peptide ingredients intended for cosmetic applications. This certification broadened the documented application scope of its manufacturing capabilities beyond pharmaceutical and research uses. CPC Scientific is part of Medtide Inc. Medtide was listed on the Main Board of the Hong Kong Stock Exchange on June 30, 2025, under stock code 03880. The listing concerns the parent group rather than a separately identified CPC Scientific listing. CPC Scientific’s brand identity is therefore primarily associated with specialized peptide and oligonucleotide contract services, regulated manufacturing, synthesis expertise, and support for customers progressing from research materials toward clinical or commercial applications.

CPC Scientific traces its origins to CPC Scientific Group, founded in 2001. The United States company was established in 2005 by Shawn Lee, Ph.D. Its initial business focused on research-grade custom peptides, catalog peptides, and Fmoc-protected amino acids. These products served researchers needing custom sequences, peptide standards, and protected amino-acid building blocks for laboratory and drug-discovery work. In 2006, CPC Scientific opened a GMP facility in Hangzhou, China. The facility marked an expansion from research supply toward regulated manufacturing and was intended to support peptide production for clinical applications. Its first inspection by the United States Food and Drug Administration took place in 2011. After that inspection, CPC Scientific began supplying pharmaceutical-grade peptides to customers in the United States. The Hangzhou site later passed a fourth FDA inspection on March 17, 2016. The company’s principal manufacturing approach is solid-phase peptide synthesis. SPPS builds a peptide chain sequentially while it remains attached to a solid support, allowing the controlled preparation of complex sequences. CPC Scientific applies this platform to research materials, active pharmaceutical ingredients, investigational drugs, and other peptide products. Researchers associated with the company have published work on peptide-synthesis techniques, including hydrocarbon-stapling approaches, and CPC Scientific-manufactured products have appeared in scientific studies. Regulatory activity continued in the 2020s. In 2024, CPC Scientific completed a fifth U.S. FDA inspection and also underwent an inspection by Australia’s Therapeutic Goods Administration. In 2025, it received ISO 22716:2007 Cosmetic GMP certification covering peptide ingredients for cosmetic applications. The certification reflects the company’s participation in a wider set of peptide applications while retaining its core emphasis on controlled synthesis and manufacturing. CPC Scientific is part of Medtide Inc., whose shares were listed on the Main Board of the Hong Kong Stock Exchange on June 30, 2025, under stock code 03880. The available reference material identifies the stock-market listing with Medtide rather than with a separately listed CPC Scientific entity. CPC Scientific therefore remains best characterized as a specialist CDMO brand within the Medtide group, serving research, clinical, and commercial customers with peptide and oligonucleotide synthesis and manufacturing capabilities.

1. 2025ISO 22716 cosmetic GMP certification

   CPC Scientific obtains ISO 22716:2007 certification for cosmetic GMP manufacturing of peptide ingredients.

   Source
2. 2025Parent company joins Hong Kong Main Board

   Medtide Inc., the parent group, is listed on the Main Board of the Hong Kong Stock Exchange under stock code 03880.

   Source
3. 2024Fifth FDA inspection and TGA inspection

   The company completes a fifth U.S. FDA inspection and is also inspected by Australia’s Therapeutic Goods Administration.

   Source
4. 2016Fourth FDA inspection passed

   CPC Scientific reports passing a fourth U.S. FDA inspection on March 17, reinforcing the regulatory record of its Hangzhou facility.

   Source
5. 2011First U.S. FDA inspection of Hangzhou site

   The Hangzhou manufacturing facility undergoes its first inspection by the U.S. Food and Drug Administration, after which the company begins supplying pharmaceutical-grade peptides to U.S. customers.

   Source
6. 2006Hangzhou GMP facility opens

   CPC Scientific opens a Good Manufacturing Practice facility in Hangzhou, China, to support peptide production for clinical use.

   Source
7. 2005United States company established

   The U.S. company is established by Shawn Lee, Ph.D., initially supplying custom and catalog peptide materials and Fmoc-protected amino acids.

   Source
8. 2001CPC Scientific Group is founded

   CPC Scientific Group is established, creating the foundation for the later United States operating company and its peptide-focused services.

   Source

A specialist peptide and oligonucleotide CDMO providing synthesis, process-development, and regulated manufacturing support from research-stage materials through clinical and commercial programs.

• Custom peptidesResearch and pharmaceutical peptides

  CPC Scientific provides custom peptide synthesis for customers requiring defined sequences rather than off-the-shelf compounds. Custom peptides can support laboratory research, assay development, drug discovery, preclinical work, and regulated development programs. The company’s peptide services extend from research-grade materials to manufacturing intended for clinical and commercial applications.

• Catalog peptidesResearch reagents

  Catalog peptides are standardized peptide products supplied for research use. They formed part of CPC Scientific’s early product range alongside custom peptides and protected amino acids, giving researchers access to recurring peptide materials without commissioning an entirely new synthesis project.

• Pharmaceutical-grade peptidesPharmaceutical manufacturing

  The company manufactures pharmaceutical-grade peptide materials for customers in regulated development and production settings. These materials may serve as active pharmaceutical ingredients, investigational-drug components, or other controlled inputs for clinical and commercial programs. Production is associated with the company’s GMP capabilities and regulatory-inspection history.

• OligonucleotidesNucleic-acid services

  Oligonucleotide synthesis and related contract services are part of CPC Scientific’s stated CDMO scope. The available reference material does not specify individual oligonucleotide product families, sequences, or commercial brand names, so this offering is best described at the service level.

• Fmoc-protected amino acidsPeptide synthesis building blocks

  Fmoc-protected amino acids were among CPC Scientific’s early offerings. These protected building blocks are used in solid-phase peptide synthesis, where temporary protection helps control the sequence-by-sequence assembly of peptide chains on a solid support.

• Cosmetic peptide ingredientsCosmetic ingredients2025

  CPC Scientific manufactures peptide ingredients for cosmetic applications. Its 2025 ISO 22716:2007 Cosmetic GMP certification documents manufacturing under a cosmetic Good Manufacturing Practice framework, although the available sources do not identify particular ingredient names or consumer-facing brands.

• 2025Add certified cosmetic peptide manufacturingStrategy

  Peptides are used not only in pharmaceutical and research settings but also as ingredients in cosmetic formulations.

  What changed. CPC Scientific obtained ISO 22716:2007 Cosmetic GMP certification for manufacturing peptide ingredients for cosmetic applications.

  Aftermath. The certification expanded the company’s documented manufacturing coverage into cosmetic peptide ingredients.

  Source
• 2024Continue international regulatory engagementOther

  CPC Scientific’s regulated manufacturing activities required ongoing oversight across the markets served by its facilities and customers.

  What changed. The company completed a fifth U.S. FDA inspection and underwent an inspection by Australia’s Therapeutic Goods Administration.

  Aftermath. The inspections extended the company’s documented regulatory history, although the available source does not provide detailed findings.

  Source
• 2006Expand into GMP peptide manufacturingStrategy

  After beginning with research-grade peptide and amino-acid products, CPC Scientific needed manufacturing infrastructure capable of supporting clinical-use materials.

  What changed. The company opened a GMP facility in Hangzhou, China.

  Aftermath. The facility became the basis for later pharmaceutical-grade peptide supply and subsequent FDA and TGA inspections.

  Source

• 2025CPC Scientific receives ISO 22716 cosmetic GMP certification

  CPC Scientific obtained ISO 22716:2007 Cosmetic Good Manufacturing Practice certification for manufacturing peptide ingredients used in cosmetic applications.

  Regulation
  Source
• 2025Medtide Inc. lists on the Hong Kong Stock Exchange

  CPC Scientific’s parent company, Medtide Inc., was listed on the Main Board of the Hong Kong Stock Exchange under stock code 03880.

  Other
  Source
• 2024CPC Scientific completes fifth U.S. FDA inspection

  CPC Scientific completed a fifth inspection by the United States Food and Drug Administration, continuing the regulatory history of its Hangzhou manufacturing facility.

  Regulation
  Source
• 2024CPC Scientific undergoes Australia TGA inspection

  The company was inspected by Australia’s Therapeutic Goods Administration as part of its continuing regulatory and quality oversight.

  Regulation
  Source

1. CPC Scientific
2. CPC Scientific official website